<DOC>
	<DOCNO>NCT01605071</DOCNO>
	<brief_summary>The aim current study test whether effect estrogen insulin metabolism depend time treatment relative woman go menopause . The investigator hypothesize estrogen improve insulin sensitivity early postmenopausal woman , decrease insulin sensitivity late postmenopausal woman .</brief_summary>
	<brief_title>Timing Estrogen After MenoPaUSe</brief_title>
	<detailed_description>Large clinical trial show reduced incidence type 2 diabetes postmenopausal woman randomize estrogen-based hormone therapy compare placebo . Moreover , study suggest development diabetes reduce postmenopausal woman use hormone therapy part postmenopausal period compare woman never use hormone therapy . Consistent , preliminary data suggest time estrogen treatment relative menopause may important determinant whether favorable effect insulin action . Our observation suggest estrogen improves insulin sensitivity early postmenopausal woman , may decrease insulin sensitivity 10 year past menopause . More study suggest estrogens divergent effect cardiovascular risk initiate close onset menopause rather distant menopause ; hypothesize also true diabetes risk . The goal study determine whether effect estrogen insulin metabolism different woman early postmenopausal compare late postmenopausal . To meet goal , propose measure insulin sensitivity woman within 6 year onset menopause 10 year beyond menopause use hormone therapy previously . All woman study two separate occasion , one day one day without short-term ( 1 week ) treatment transdermal estradiol . We expect estradiol increase insulin sensitivity early postmenopausal woman decrease insulin sensitivity late postmenopausal woman . We also expect estrogen receptor fat muscle may change increase time menopause . Thus , collect fat muscle biopsy compare change estrogen receptor early late postmenopausal woman response 1 week estradiol treatment . We believe study provide evidence benefit estradiol insulin sensitivity administer early , late , menopause ; likely contribute delay onset type 2 diabetes postmenopausal woman .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>aged 4570 yr postmenopausal ( menses ≥12 mo bilateral oophorectomy FSH &gt; 30 IU/L ) ≤6yrs ≥10yrs menopause ( last menses oophorectomy ) BMI &lt; 30 kg/m2 weight stable ( ±2kg past 2mo ) nonsmoker sedentary moderately active ( &lt; 3 days/wk structure exercise ) naïve estrogenbased hormone therapy ( previous use ≤6 month ) CBC , CMP TSH value within normal range specify lab underwent partial hysterectomy ( i.e. , one ovary leave intact ) underwent menopause ( natural , chemical , surgical ) prior age 45yr &gt; 6yr &lt; 10yr menopause ( last menses oophorectomy ) previously use ( &gt; 6 mo ) currently use formulation estrogenbased HT ( e.g. , oral Premarin , transdermal 17betaestradiol , selective estrogen receptor modulators ) T2DM treat glucoselowering/ insulin sensitize medication uncontrolled hypertension ( SBP &gt; 140 and/or DBP &gt; 90 mmHg ) hypertriglyceridemia ( &gt; 400 mg/dL ) contraindication estrogen therapy ( history venous thromboembolism , heart disease , myocardial infarction , hormone sensitive cancer ) contraindication biopsy ( severe anemia , blood clot disorder )</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>menopause</keyword>
	<keyword>estrogen</keyword>
	<keyword>insulin sensitivity</keyword>
	<keyword>estrogen receptor</keyword>
</DOC>